New kidney drug interaction study launches in healthy volunteers
NCT ID NCT07181265
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage study tests how a new drug called JMKX003142 interacts with two common medications—amiodarone (for heart rhythm) and febuxostat (for gout)—in 48 healthy Chinese adults. Participants will take the drugs in sequence to measure how their bodies process them. The goal is to gather safety and dosing information, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JMKX003142
- What this could lead to
- If successful, this study could help determine safe dosing of JMKX003142 when taken with other common drugs, supporting future trials for polycystic kidney disease.
- What could go wrong
- This is an early Phase 1 study in healthy volunteers, not patients. It only measures drug levels, not effectiveness. Results may not predict real-world outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Carb diet calm kidney disease inflammation?
- Large study tracks kidney disease progression in thousands of patients
- New hope for dialysis patients: non-surgical kidney reduction could clear the way for transplant
- Could a drug for acromegaly protect kidneys in polycystic disease?
- Drug interaction study: VX-407 and oral contraceptives
- Could a keto diet help slow kidney disease? new study seeks answers